Previous 10 | Next 10 |
2023-07-19 17:50:15 ET Summary Immunovant, Inc. received additional validation with anti-FcRn achieved as competitor argenx achieves primary endpoint in phase 2 study using VYVGART for the treatment of patients with CIDP. Immunovant expects to release results from its phase 2b stu...
2023-07-17 13:26:32 ET Shares of Immunovant ( NASDAQ: IMVT ) jumped 14% midday Monday amid the release of positive data for Argenx's ( ARGX ) drug Vyvgart Hytrulo, which is in the same drug class as Immunovant's drug candidate IMVT-1402. Argenx reported earlier Monday that a...
2023-07-13 19:22:04 ET Roivant Sciences ( NASDAQ: ROIV ) is close to selling its its ulcerative colitis drug candidate RVT-3101 to Roche ( OTCQX:RHHBY ) through deal that could be worth more than $7B, according to the Wall Street Journal. Roivant has been developing the drug...
BASEL, Switzerland, LONDON, and NEW YORK, July 11, 2023 (GLOBE NEWSWIRE) -- Fast Company today announced its fifth annual Best Workplaces for Innovators list, honoring organizations and businesses that demonstrate an inspiring commitment to encourage and develop innovation at all levels. ...
2023-07-10 08:48:44 ET Summary Roivant Sciences' ulcerative colitis therapy, RVT-3101, shows promising results in Phase 2b trial, attracting interest from major pharmaceutical companies. The company ended the fiscal year with a cash position of approximately $1.7 billion, with los...
2023-07-06 14:55:08 ET Shares of U.K.-based biotech Roivant Sciences ( NASDAQ: ROIV ) reached a session high on Thursday triggering a trading halt after Bloomberg reported that the company has attracted biopharma interest in $7B bowel drug. Accordig to the report, large bi...
2023-07-02 07:18:39 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . For further details see: Wall Street Breakfast: The Week Ahead
2023-06-28 15:47:58 ET Shares of Roivant Sciences (NASDAQ: ROIV) were up more than 11% by 3 p.m. ET on Wednesday after the pharmaceutical company that specializes in smaller portfolio companies, called vants, released fourth-quarter and 2023 fiscal-year earnings. The stock is up...
RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across all doses A Phase 2 study of RVT-3101 in Crohn’s disease has been initiated with to...
2023-06-28 07:24:17 ET Roivant Sciences press release ( NASDAQ: ROIV ): Q4 GAAP EPS of -$0.20 beats by $0.18 . Revenue of $27.38M (+197.0% Y/Y) beats by $9.18M . For further details see: Roivant Sciences GAAP EPS of -$0.20 beats by $0.18, revenue of $27.3...
News, Short Squeeze, Breakout and More Instantly...
Roivant Sciences Ltd. Company Name:
ROIV Stock Symbol:
NASDAQ Market:
Roivant Sciences Ltd. Website:
2024-07-11 10:45:04 ET Rivian Automotive Inc (RIVN) RIVN is trading UP for the last 5 days, and it at trading at $16.74 with volume of 18,885,597 and a one day change of $0.37 (2.23%). Rivian Automotive Inc has a 52-week low of 12.15 and a 52-week high of $32.60. The business's 50-d...
2024-06-02 17:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update. Once-daily brepocitinib produced the best Treatment Failure...